openPR Logo
Press release

Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape

DelveInsight, the leading market research and consulting company has added a new report “Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016” to its portfolio.

The Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes :

• 215+ products and 50+ different technologies along with 70+ companies actively involved in drug development. There are 5 drugs in phase III, 22 in phase II, 42 in phase I, and 87 in pre-clinical, 28 in discovery, 16 dormant and 19 discontinued drugs.
• Brentuximab Vedotin, developed by Seattle Genetics, is the leading product.
• R&D activities and technologies used along with the pipeline molecules in development.
• Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
• Information related to collaborations, in-licensing and out-licensing deals.

DelveInsights, Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the in-depth analysis of Antibody Drug Conjugate Landscape across the globe. Therefore the report on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provide information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 2950 as a single user license, USD 5900 as a site license and USD 8850 as a Global/Enterprise License.

For more information on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report, email at info@delveInsight.com

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

New Delhi, Delhi, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape here

News-ID: 324632 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Antibody

Evolving Market Trends In The Antibody Drug Conjugates Industry: Regulation On A …
The Antibody Drug Conjugates Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Antibody Drug Conjugates Market Size During the Forecast Period? The market size for antibody drug conjugates has experienced rapid expansion in the past few years. It's projected to rise from
TIGIT Antibody Clinical Trials FDA Approval Market Size Anti TGIT Antibody Sales …
Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028 Report Highlights: • Anti TIGIT Antibodies In Clinical Trials: > 50 Antibodies • First Anti TIGIT Antibody To Get Approval Within Next 5 Years • Global Anti TIGIT Antibodies Clinical Pipeline Insight By Company, Indication and Phase • Insight On More Than 50 Anti TIGIT Antibodies In Clinical Trials • Anti TIGIT Antibodies Market Trends by Indication & Country • Global Anti TIGIT Antibodies Market Dynamics Download Report: https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene In recent years, the global
Mammalian Polyclonal IgG Antibody Market, Mammalian Polyclonal IgG Antibody Mark …
"According to the research report, the global inspection machines market was valued at USD 845.21 million in 2022 and is expected to reach USD 1,437.59 million by 2032, to grow at a CAGR of 5.5% during the forecast period." Request Our Free Sample Report for Inspection Machines Market Insights and Emerging Trends @ https://www.polarismarketresearch.com/industry-analysis/inspection-machines-market/request-for-sample Report Overview Polaris Market Research, a leading global market research and consulting company, has recently published its latest report
Global Combination Antibody Therapy Market 2022: Antibody/Antibody Combination S …
The combination antibody therapy market is expected to experience significant growth in the coming years. Combination antibody therapy involves the use of two or more monoclonal antibodies (mAbs) in combination to treat various diseases, such as cancer, autoimmune disorders, and infectious diseases. Request For Free Sample Report of "Combination Antibody Therapy Market"@ https://www.persistencemarketresearch.com/samples/11740 Combination antibody therapy has several potential benefits over single-agent therapies, including increased efficacy, improved patient outcomes, and reduced toxicity.
Global Combination Antibody Therapy Market 2022: Antibody/Antibody Combination S …
Combination antibody therapy involves the use of two or more antibodies to target and treat a specific disease or condition. This type of therapy is often used in cancer treatment, as it can be more effective at targeting and killing cancer cells than single-antibody therapies. Combination antibody therapy can also be used to treat a range of other diseases and conditions, including autoimmune diseases, infectious diseases, and allergic conditions. Request For
Procalcitonin Antibody Market Report 2018: Segmentation by Type (Polyclonal Proc …
Global Procalcitonin Antibody market research report provides company profile for Ningbo Medicalsystem Biotechnology, Snibe, Vazyme Biotech, Getein Biotech, Hotgen Biotech, Lumigenex, Shanghai Medicine'nest Pharmaceutical, Thermo Fisher, Roche Diagnostics, bioMerieux, HyTest, Wondfo and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for